Archive | October, 2021

RESI November Deadline Tomorrow

7 Oct

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claire

Life Science Nation’s last conference of the year, RESI Partnering Week (RPW), November 16-18, is actively taking registrations from startup companies, investors, service providers, and more across the globe and the super early bird registration rates end this week. The conference is unique in that it features three tracks of content around drugs, devices, digital health, global investment, AI applications, and age-tech and senior care across panels, fireside chats, and workshops, as well as more Innovator’s Pitch Challenge (IPC) sessions than ever before.

Last year’s RESI November event attracted over 350+ investors across ten different categories of investors from venture capital, family office/private wealth, big pharma, large medtech, and more. Do not miss the opportunity to close off this year with another robust partnering event at an unbeatable price! Sign up by Friday, October 8 to save $200!

Register-now-button-new

Confirmed Digital RESI November Investors

As of October 7


RESI-NOV-Banner-3050x-1050

Sometimes Money Isn’t Enough

7 Oct

By Karen Deyo, Director of Investor Research, Israel BD, LSN; Gregory Mannix, Vice President International Business Development, General Manager Europe, LSN

Life Science Nation (LSN) and the Redefining Early Stage Investment (RESI) conference series are built on the belief that a startup can improve its fundraising success by partnering often and making sure that the investors and strategic partners they reach out to are a fit for their technology and stage of development. However, while fundraising is a key piece of the puzzle to achieving success, it is not the only piece.

The other pillar of the RESI conference is our service provider attendees, many of whom sponsor the events. These companies can play a crucial role in giving startups advice to navigate the complex path of taking a technology to a finished product. Simply put, a lack of funding is not the only reason a company may fail – if the company makes an early mistake through inexperience, this can cause issues down the road when they can no longer be fixed.

The service providers who attend RESI can offer valuable insight to early-stage companies based on years, and often decades, of experience working in this space. Taking the opportunity to connect with them at RESI can help a startup achieve that next milestone on the most efficient path. It is often worth the additional cost to know that it is done right and often much faster than achieved in-house.

Sponsors at RESI Partnering Week represent a wide array of valuable services that early-stage companies will benefit from, and they offer guidance and workshops at RESI. Here are some examples:

  • MWE has offered workshops on Negotiating Term Sheets—always a favorite at RESI—and on Commercialization of AI Technologies.
  • Burns & Levinson has shared guidance on such relevant topics as Intellectual Property and Cross-Border Transactions.
  • First Republic Bank discussed the wide array of services that banks can offer to startups.
  • Venture Valuation offered valuable insight on Company Valuation for Fundraising

Other sponsors can provide information on topics ranging from insurance needs for life science companies (Medmarc) to Clinical Trials in Australia (Avance Clinical) to financing of scientific equipment (Boldview Capital), to name just a few.

Aside from information and insight, the great service provider companies that come to RESI are available to help early-stage companies on the long journey to commercialization or exit. Learn more about sponsorship opportunities and how LSN’s business development team can help you reach your goals.

RESI-NOV-Banner-3050x-1050

Hot Investor Mandate: Healthcare & Life Sciences Investment Branch of Global Manufacturing Company Invests in Medical Devices and Software-Enabled Technologies

7 Oct

A healthcare and life sciences branch of a leading manufacturing company invests primarily in Series A or later companies in digital health, medical devices, genomics and molecular diagnostics technologies, but can expand their focus conditionally. While some of their investments are strategic, the firm is willing to invest outside of corporate strategic areas. The firm is a global investor, and can act as both a strategic partner and a financial investor, depending on the company.

The firm can invest as a strategic manufacturing company, but is also interested in software-enabled technologies and connected devices. While the firm may consider PMA devices, most investments are in 510k-pathway products. For purely digital health products, such as IoT technology, the firm would like to see some revenue and market traction before investing. For both medical devices and digital health, the firm is agnostic to indication. The firm’s interest in genomics and molecular diagnostics primarily relate to the oncology space, and prefer to see technologies with some clinical data.

The firm may take a board seat after investing, if they are the lead or if they have strategic value to offer the portfolio company, but will generally not take a board seat if they are co-investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Pharmaceutical Company Seeks Therapeutics in Reproductive, Maternal Health, GI, With Additional Interests in AI Drug Discovery Platforms

7 Oct

A pharmaceutical that has primarily focused on reproductive and maternal health is now looking to expand into other indications. Additionally, the firm is interested in AI drug development platforms. The firm is willing to partner with early to late stage companies, and will partner globally.


The firm is interested in therapeutics in the areas of reproductive and maternal health, and is interested in expanding into the area of GI, such as therapeutics treating IBD and UC, and is interested in the microbiome as well. The firm is interested in all modalities. In addition to therapeutics, the firm is also interested in AI platforms for drug discovery and biomarker identification.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Corporate Venture Firm Interested in Seed to Series A Digital Health Companies Working on Better Data Collection, Remote Monitoring, Etc.

7 Oct

A corporate venture firm located in the USA has 4 area of focus: fintech, digital health, data analytics and insurtech. The firm has made 36 investments total and the average check size is around $1M in Seed or Series A rounds. The firm’s capital structure is typically SAFEs and priced rounds. The firm also has a second venture fund of $5M for Pre-seed and Seed rounds, and this fund is exclusively for companies located in their state. The firm invests across the US and Canada.

The firm’s main areas of focus are fintech, digital health, data analytics and insurtech. Since the firm is a branch of a legacy life insurance company, within the insurtech and fintech sectors, the firm focuses on the evolution of the consumer wallet and how they can develop new products in partnership with startups. Within the digital health sector, the firm focuses on data collection and items that can influence their underwriting models, electronic med records, wearables, remote monitoring devices, and the firm is looking more into implantables in the future. The firm isn’t interested in physician scaling tools, or any companies focused solely on hardware. The firm is open to pre-prototype companies.

The firm looks for diverse management teams, with 2 or 3 founders. The firm likes to see subject matter expertise, traction in product development or alpha/beta testing, and repeat founders are a plus, but not required. The firm also looks for a strong advisor team. The firm typically co-invests.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA VC Firm Invests in Global Biotech, Medtech, AI and ML with Strong Interests in Oncology, Mental Health, Respiratory, Women’s Health, and More

7 Oct

A USA-based venture capital firm founded in 2020 focuses on investing, building and scaling life science start ups. The goal is to co-innovate and grow with the startups they invest in. The firm has a fund that is financed by numerous angel groups as well as a hedge fund. Investments are mainly in the form of equity and in-licensing, but the firm is flexible on a case-by-case basis with convertible notes. The firm has 7 life science companies in their portfolio to date. The firm’s main focus is biotech, medtech, and AI and machine learning technologies. The firm’s goal is to build innovations in hospitals that transform the lives of patients and make doctors jobs easier. The firm focuses on Pre-Seed, Seed and Series A financing rounds. The firm is open to global opportunities.

The firm’s focus on AI, machine learning, and other biotech/medtech technologies, and within those domains, are open to all 4 main sectors. The firm looks for technologies in: consumer health, connected health practices, patient engagement related arenas, telehealth, distal therapeutics, and consumer health solutions and services. The firm doesn’t focus on traditional medical devices, but is looking to invest in “smart” medical devices that support connected health practices. The firm is open to most indications, especially oncology, women’s health, mental health, respiratory, cardiology, and pediatrics. The firm is not interested in drugs therapeutics or immunology with the exception of mRNA vaccines. The firm invests in pre-clinical companies.

The firm is looking for a team that they can work and co-innovate with and do channel partnering with to scale their businesses. For this firm, the concept or idea is the most important part and they are looking for more than what companies built today, they look for the future impact. Interested companies should have management teams that are in alignment with the firm’s values and that their end outcome is patient success. The firm can lead or co-invest on a case by case basis and will seek board seat representation on a case by case basis as well.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot AI Mandate: California-based VC Interested in Platform-based & AI or ML-based Drug Discovery Companies

5 Oct

A VC fund based in Los Angeles founded in 2016 is investing out of a $261M fund. The firm invests in many sectors, including cloud-based enterprise SaaS, Property Tech, and life sciences & healthcare. Within the life sciences, the firm is interested in therapeutics, medical device, digital health and healthcare IT companies. The firm invests in Series A and later rounds, and can invest anywhere from $1-20M in the initial check, and may participate in follow-on rounds. The firm is generally focused on investing in companies based in North America, but will consider global companies if they have a large presence in the US and are focused on the US market.

The firm will invest in therapeutics, medical device, digital health and healthcare IT companies. Within therapeutics, the firm is seeking companies in IND or later stages. In addition, the firm is interested in platform technologies, and will also invest in AI or machine learning-based drug discovery companies. The firm will not invest in single asset or single modality companies. For medical devices, the firm primarily invests in 510K pathway devices that are FDA approved. The firm will not invest in DTC devices, and is less likely to consider de novo or PMA devices as well. Furthermore, the firm is most interested in devices that have a continuing source of revenue, such as a software application component. For digital health and healthcare IT companies, the firm is primarily focused on companies with B2B services, and will not invest in digital therapeutics. The firm is interested in companies that have greater than of $3M in ARR.

The firm is willing to lead or co-invest, but will generally take a board seat if they lead the investment round.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.